Key facts: 68% lower recurrence risk; record close; targets raised

CG Oncology (CGON) reported Phase 3 data showing 68% lower recurrence risk for cretostimogene with no serious side effects. Shares rose 14% to a record close of $84.78. Four firms raised price targets: JPMorgan to $113, Truist to $100, Wedbush to $91, and HC Wainwright to $115.

Original reporting
Published Nov 18, 2026, 8:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 8:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Key facts: 68% lower recurrence risk; record close; targets raised — source image
Decision brief

The 30-second read

$CGONBullishHigh
01

Why it matters

The data represents a material, first‑report clinical breakthrough that can materially affect the stock price.

02

Market read

First disclosure of pivotal trial data; likely triggers a sharp rally in CGON and may lift related biotech names.

03

What to watch

Potential regulatory hurdles or competition from other oncology therapies.

Relevance 9/10Novelty 9/10Timing: today

Background

The article is a brief AI‑generated summary of CG Oncology's Phase 3 trial announcement.

Company-level read

Ticker impact

$CGONBullishHigh confidence
Context

CG Oncology reported Phase 3 data showing a 68% lower recurrence risk, driving a 14% price jump to a record $84.78.

Expected impact

upward pressure as investors price in the strong efficacy data

Evidence & confidence

First disclosure of pivotal trial data for a listed biotech typically triggers a significant rally.

Market effects

Biotech sector may see broader gains as investors reassess oncology pipelines.

US biotech stocks could benefit from the news.

Limited to markets tracking US-listed biotech firms.

Counterpoint

Skeptics may question long-term commercial viability despite early efficacy.

Key entities

  • CG Oncology

    US‑listed biotech company (ticker CGON) reporting Phase 3 trial results.

Related articles

$CGONMed

CG Oncology Stock Falls 7% as RBC Downgrade Cools Rally After Bladder Cancer Drug Cuts Recurrence Risk by 68%

CG Oncology Inc. shares fell 7.53% on Tuesday, after a 14% rise on Monday following positive trial results for its bladder cancer treatment. RBC downgraded the stock to Sector Perform, citing regulatory path, despite raising its price target to $97. The Phase 3 trial showed a 68% reduction in cancer recurrence risk. Other analysts raised price targets, with JPMorgan at $113 and Truist at $100.

$CGONMed

Truist raises CG Oncology stock price target on trial results

Truist Securities raised its price target for CG Oncology (CGON) to $100 from $85, citing positive PIVOT-006 trial results. The stock is up 16.7% over the past week. Full data will be presented in December 2026, with FDA submissions expected in 2027. Analysts have revised earnings estimates upward, highlighting a multi-billion-dollar market opportunity.

$CGONMed

JPMorgan raises CG Oncology stock price target on trial data

JPMorgan raised its price target for CG Oncology (CGON) to $113 from $96, citing positive trial data and regulatory updates. The stock, currently at $84.78, has surged over 104% year-to-date. JPMorgan increased its success probability for Creto in bladder cancer treatments, projecting $1.2B and $1.0B in U.S. peak sales by 2037 for different settings. RBC Capital downgraded CGON to Sector Perform but raised its target to $97.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.